chain of custody comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
| Property | Value | Notes |
|---|---|---|
| Typical purity assay | reversed-phase HPLC, 220 nm | Amide-bond detection for the peptide backbone |
| Identity confirmation | electrospray mass spectrometry | Peptide mapping used for sequence coverage |
| Related substances | deamidated and oxidised forms | Truncated sequences also monitored |
| Powder storage | -20 degrees Celsius | Keep sealed, dry, and protected from light |
| Solution storage | 2 to 8 degrees Celsius | Avoid repeated freeze-thaw cycling |
肽类的主要降解路径包括天冬酰胺脱酰胺、甲硫氨酸氧化、天冬氨酸异构化以及由 β-折叠驱动的聚集，这些反应对 pH 与缓冲液种类较为敏感。磷酸盐、丙二醇与苯酚等辅料会影响局部微环境与界面行为。强制降解研究借助高温、强光、氧化剂与极端 pH 暴露来预测产物谱。关于长期室温存放的数据相对有限，超出标签条件的稳定性仍属开放问题，需要在具体制剂中通过实时与加速试验加以确认。
容器与密封系统同样参与稳定性表现。硅油涂层、胶塞材质与顶空氧含量可能改变聚集速率与氧化水平。分析结果因此需要在完整包装形式下评估，而不能仅凭原料药数据推断。法规文件通常要求同时提交批次数据与代表性容器中的稳定性趋势。
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
By the end of the year, there were 12,000 Cuban soldiers inside Angola, nearly the size of the entire SADF presence in South West Africa. The FNLA suffered a crushing defeat at the Battle of Quifangondo when it attempted to take Luanda on 10 November, and the capital remained in FAPLA hands by independence.
=== Vaccine manufacturers === The companies with the highest market share in vaccine production are Merck, Sanofi, GlaxoSmithKline, Pfizer and Novartis, with 70% of vaccine sales concentrated in the EU or US as of 2013. Vaccine manufacturing plants require large capital investments ($50 million up to $300 million) and may take between 4 and 6 years to construct, with the full process of vaccine development taking between 10 and 15 years. Manufacturing in developing countries is playing an increasing role in supplying these countries, specifically with regards to older vaccines and in Brazil, India and China. The manufacturers in India are the most advanced in the developing world and include the Serum Institute of India, one of the largest producers of vaccines by number of doses and an innovator in processes, recently improving efficiency of producing the measles vaccine by 10 to 20-fold, due to switching to a MRC-5 cell culture instead of chicken eggs. China's manufacturing capabilities are focused on supplying their own domestic need, with Sinopharm (CNPGC) alone providing over 85% of the doses for 14 different vaccines in China. Brazil is approaching the point of supplying its own domestic needs using technology transferred from the developed world.
On 2 August, Sanlu's Board decided to issue a trade recall to the wholesalers but did not notify them that the product was contaminated; however, Shijiazhuang's deputy mayor, who was invited to attend, rejected trade recall and instructed the Board to "shut the mouths of the victims by money", "wait until the end of 2008 Beijing Olympics to end smoothly and then the provincial police would hunt the perpetrators". New Zealand dairy giant Fonterra, which owned a 43% stake in Sanlu, were alerted to the contamination on 2 August. Fonterra alerted the New Zealand government and the NZ government confronted the Chinese government on 8 September. The Chinese government made the scandal public on 13 September. After the initial focus on Sanlu, further government inspections revealed that products from 21 other companies were also tainted, including those from Arla Foods–Mengniu, Yili, and Yashili. While more and more cases reached hospitals around the nation from December 2007, the first report to the government by any hospital was made on 16 July. The issue raised concerns about food safety and political corruption in China and damaged the reputation of the country's food exports. The World Health Organization called the incident "deplorable" and at least 11 foreign countries halted all imports of Chinese dairy products.
A steroid is an organic compound with four fused rings (designated A, B, C, and D) arranged in a specific molecular configuration. Steroids have two principal biological functions: as important components of cell membranes that alter membrane fluidity; and as signaling molecules. Examples include the lipid cholesterol, sex hormones estradiol and testosterone, anabolic steroids, and the anti-inflammatory corticosteroid drug dexamethasone. Hundreds of steroids are found in fungi, plants, and animals. All steroids are manufactured in cells from sterol precursors: cholesterol and lanosterol (in opisthokonts), or cycloartenol (in plants). All three of these molecules are produced via cyclization of the triterpene squalene.
Sources: en.wikipedia.org
== History == OFM was developed and is manufactured by Aroa Biosurgery Limited (New Zealand, formerly Mesynthes Limited, New Zealand) and was first patented in 2008 and described in the scientific literature in 2010. OFM is manufactured from sheep rumen tissue, using a process of decellularization to selectively remove the unwanted sheep cells and cell components to leave an intact and functional extracellular matrix. OFM comprises a special layer of tissue found in rumen, the propria submucosa, which is structurally and functionally distinct from the submucosa of other gastrointestinal tissues. OFM was first cleared by the FDA in 2009 for the treatment of wounds. Since 2008 there have been >70 publications describing OFM and its clinical applications, and over 6 million clinical applications of OFM-based devices.
== History == Elagolix was first described in the literature in 2005. It was originally developed by the pharmaceutical company Neurocrine Biosciences, and was later developed together by Neurocrine Biosciences and AbbVie (previously Abbott Laboratories). In June 2010, Neurocrine Biosciences and Abbott announced a global agreement to develop and commercialize elagolix for the treatment of endometriosis. The medication completed phase III clinical trials for endometriosis in November 2016. Two phase III clinical trials, the Elaris Endometriosis I and II (EM-I and EM-II) studies, were conducted. The studies included almost 1,700 women, about 950 of whom were treated with elagolix. In September 2017, AbbVie filed a New Drug Application (NDA) for elagolix for the treatment of pain associated with endometriosis in the United States. The medication was approved by the FDA for the treatment of endometriosis-associated pain in the United States on 23 July 2018. It was the first new medication to be approved by the FDA for the treatment of endometriosis in more than a decade. Elagolix was the first member of a new class of GnRH modulators described as "second-generation" due to their non-peptide and small-molecule nature and oral activity to be marketed. A second member of this group, relugolix (brand name Relumina), was introduced in Japan in January 2019. In addition to endometriosis, elagolix is under development for the treatment of uterine fibroids and menorrhagia. It is in phase III clinical trials for these indications.
=== Indicators of quality === High-quality honey can be distinguished by fragrance, taste, and consistency. Ripe, freshly collected, high-quality honey at 20 °C (68 °F) should flow from a knife in a straight stream, without breaking into separate drops. After falling down, the honey should form a bead. The honey, when poured, should form small, temporary layers that disappear fairly quickly, indicating high viscosity. If not, it indicates honey with excessive water content of over 20%, not suitable for long-term preservation. In jars, fresh honey should appear as a pure, consistent fluid, and should not set in layers. Within a few weeks to a few months of extraction, many varieties of honey crystallize into a cream-colored solid. Some varieties of honey, including tupelo, acacia, and sage, crystallize less regularly. Honey may be heated during bottling at temperatures of 40–49 °C (104–120 °F) to delay or inhibit crystallization. Overheating is indicated by change in enzyme levels, for instance, diastase activity, which can be determined with the Schade or the Phadebas methods. A fluffy film on the surface of the honey (like a white foam), or marble-colored or white-spotted crystallization on a container's sides, is formed by air bubbles trapped during the bottling process. A 2008 Italian study determined that nuclear magnetic resonance spectroscopy can be used to distinguish between different honey types, and can be used to pinpoint the area where it was produced.
Journalist Dmitry Kiselyov listed the targets in the United States, which includes The Pentagon, Camp David, Fort Ritchie, McClellan Air Force Base, and Jim Creek Naval Radio Station. Kremlin spokesperson Dmitry Peskov denies the existence of the target list. On February 24, 2022, in a televised address preceding the start of the Russo-Ukrainian war (2022–present), Russian President Vladimir Putin stated that Russia "is today one of the most powerful nuclear powers in the world... No one should have any doubts that a direct attack on our country will lead to defeat and dire consequences for any potential aggressor." Later in the same speech, Putin stated: "Now a few important, very important words for those who may be tempted to intervene in ongoing events. Whoever tries to hinder us, and even more so to create threats for our country, for our people, should know that Russia's response will be immediate and will lead you to such consequences that you have never experienced in your history." On February 27, 2022, Putin publicly put his nuclear forces on alert, stating that NATO powers had made "aggressive statements". On April 14, The New York Times reported comments by CIA director William Burns, who said "potential desperation" could lead President Putin to order the use of tactical nuclear weapons.
Two major principalities survived east of the Weser after the Napoleonic Wars: the Kingdom of Hanover and the Duchy of Brunswick (after 1866 Hanover became a Prussian province; after 1919 Brunswick became a free state). Historically a close tie existed between the royal house of Hanover (Electorate of Hanover) and the United Kingdom of Great Britain and Ireland as a result of their personal union in the 18th century (the personal union was dissolved when Victoria became the Queen of the United Kingdom in 1837 because Hanover did not allow female rulers). West of the River Hunte a "de-Westphalianising process" began in 1815. After the Congress of Vienna the territories of the later administrative regions (Regierungsbezirke) of Osnabrück and Aurich transferred to the Kingdom of Hanover. The Grand Duchy of Oldenburg and the Principality of Schaumburg-Lippe retained state autonomy. Nevertheless, the entire Weser-Ems region (including the city of Bremen) were grouped in 1920 into a Lower Saxon Constituency Association (Wahlkreisverband IX (Niedersachsen)). This indicates that at that time the western administrations of the Prussian Province of Hanover and the state of Oldenburg were perceived as being "Lower Saxon". The forerunners of today's state of Lower Saxony were lands that were geographically and, to some extent, institutionally interrelated from very early on.
Sources: en.wikipedia.org
== See also == Archive Team – Group dedicated to web archiving and digital preservation Dead Internet theory Digital preservation – Practice to keep digital assets accessible in long term Infodemic – Rapid spread of accurate and inaccurate information Lost media – General term for inaccessible media Software rot – Degradation or loss of the use of software over time
== Structure == Somatotropic cells constitute about 30−40% of anterior pituitary cells. They release growth hormone (GH) in response to growth hormone releasing hormone (GHRH, or somatocrinin) or are inhibited by GHIH (somatostatin), both received from the hypothalamus via the hypophyseal portal system vein and the secondary plexus.
=== Jordan: Bring Out The Boar === First Aired: 23 December 2010 Meet Jordan, a loud mouthed bully who calls himself the boar. He makes life miserable for twins, Austin & Micah, since one of them is going to nursing school. His real name is Jordan Rush. The bad part of it is that he's a cop's son, so he says he's "At the Top of the Food Chain". So Mayhem brings in MMA Fighter Joe Riggs with a record of 34 wins and 12 losses, to teach Jordan a lesson. In the first round, he tapped out five times. During the second round, Joe finished Jordan off via TKO. Austin and Micah won $10,000. After the fight, a humbled Jordan apologized for his behavior.
== History == The ridge was named in 1907 by Mary Schäffer, the same year that Jasper National Park was established. In her book, "A Hunter of Peace," Mary wrote: "A short distance beyond the rock-slide and on the river's right, begins a low, rocky ridge, which for length and unadulterated ugliness cannot be beaten. We trailed it for a day and a half and then named it The Endless Chain, well named too, for on reaching the Athabasca shores, we found that it still stretched on in an unbroken line for miles down the river." The toponym was officially adopted in 1947 by the Geographical Names Board of Canada.
==== Member of the Order of the British Empire (MBE) ==== Civil Division Harcourt Thomas Bastian. For services to the economic development of the country. Fannie Suzanne Bethel, . For services to education and the community. Wilton Eric Darville. For services as a public officer and a trade unionist. Loretta Minnis. For services to education. Lamour Rolle. For community service to the Island of Bimini. Felix Nathaniel Stubbs. For services to the community, especially to youth.
Sources: en.wikipedia.org
Purity is commonly expressed as the percentage of the main peak relative to all integrated peaks in a reversed-phase chromatogram. Related substances and counter-ions are reported separately. Values obtained with different detectors are not always directly comparable.
Aggregation is driven by hydrophobic contacts, especially those involving the fatty acid side chain, and is accelerated by heat, agitation, and repeated freezing and thawing. Low pH and suitable excipients can reduce the rate. The tendency differs between formulations.
Dry powder has low molecular mobility and tolerates colder storage for longer periods. Water enables hydrolysis and conformational change, so dissolved material is kept refrigerated and used within a shorter window.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.